PRISM BioLab Co.,LTD (206A.T) Stock Price, Financials & Summary | drillr

Skip to content

Sign in Sign up

Price chart

Aug 20Aug 25Aug 28Sep 2Sep 7Sep 10Sep 15Sep 18

Key dataSep 18, 2026

OpenJPY 163.00

From 52W high−27.95%

Volume41500.00

Market capJPY 6.09B

P/E (TTM)—

P/S (TTM)8.3x

Div yield—

Key dataSep 18, 2026

Open

JPY 163.00

From 52W high

−27.95%

Volume

41500.00

Market cap

JPY 6.09B

ValuationView details →

P/E (Fwd)

—

EV/EBITDA

−4.4x

P/E (TTM)

—

RSI (14)

51.9

MomentumView details →

1D Return

+3.13%

YTD Return

+8.33%

ValuationView details →

P/E (Fwd)

—

P/E (TTM)

—

EV/EBITDA

−4.4x

EV/Sales

5.1x

P/S (TTM)

8.3x

P/B (TTM)

3.2x

ProfitabilityView details →

Gross Margin

39.44%

Net Margin

−135.53%

EBITDA Margin

—

ROE (TTM)

−38.01%

ROA (TTM)

−30.88%

Asset Turnover

0.22x

GrowthView details →

Revenue YoY

—

EPS YoY

—

FCF YoY

—

Revenue CAGR 3Y

+121.97%

EPS CAGR 3Y

+31.94%

EBITDA YoY

—

MomentumView details →

1D Return

+3.13%

YTD Return

+8.33%

1Y Return

−2.31%

RSI (14)

51.9

vs 50D SMA

+3.86%

vs 200D SMA

−0.95%

Capital & dividendView details →

Debt/Equity

—

Current Ratio

5.31x

Quick Ratio

5.31x

Div Yield

—

Div Rate

—

Div Growth 1Y

—

EarningsView details →

EPS (Actual)

—

EPS Surprise

—

Beats (12Q)

—

Next Q EPS Est

—

Avg Surprise (4Q)

—

Rev Surprise

—

Financials snapshotView financials →

Revenue (TTM)

684.00M

Net Income (TTM)

−927.00M

Op. CF (TTM)

—

Next earningsNov 13, 2026 →

Latest newsMore news →

PRISM BioLab announced its financial results for the third quarter of fiscal year ending September 2026, reporting a net loss of 840 million yen for the cumulative nine months (October 2025-June 2026), widening from an 800 million yen loss a year earlier, while the April-June quarter net loss narrowed to 240 million yen from 320 million yen.38d ago

Similar companies

Noile-Immune Biotech Inc.4893.T Cyfuse Biomedical K.K.4892.T TMS Co.,Ltd.4891.T Chiome Bioscience Inc.4583.T BrightPath Biotherapeutics Co.,Ltd.4594.T NIPPON CHEMIPHAR CO.,LTD.4539.T Find similar companies →

Latest newsMore news →

PRISM BioLab announced its financial results for the third quarter of fiscal year ending September 2026, reporting a net loss of 840 million yen for the cumulative nine months (October 2025-June 2026), widening from an 800 million yen loss a year earlier, while the April-June quarter net loss narrowed to 240 million yen from 320 million yen.38d ago